POLY MEDICURE LIMITED

Poly Medicure Limited held its Q1 FY27 earnings conference call on August 10, 2026, where management discussed the company's strategic vision, PolyMed 3.0, aimed at doubling revenue by FY30 through organic and inorganic growth. The standalone revenue for Q1 was reported at INR431 crores, reflecting a 12.3% increase, with domestic revenue growing by 16.2%. The consolidated revenue reached INR525 crores, up 30.3%, aided by acquisitions. Management highlighted a strong gross profit margin of 73.4% and an operating EBITDA margin of 24.1%. Challenges included a 32% de-growth in the Middle East due to ongoing crises, but management expressed optimism about future growth in international markets. The company maintained its revenue guidance for FY27, projecting INR2,300 to INR2,400 crores on a consolidated basis. Management also noted ongoing investments in new medical devices and clinical studies supported by government aid.

Management expressed optimism about growth and strategic initiatives.